ReviewAlimentary pharmacology & therapeutics2026
Review Article: Advances in the Diagnosis of Dysplasia in Barrett's Oesophagus.
Review in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review Article: Advances in the Diagnosis of Dysplasia in Barrett's Oesophagus.Alimentary pharmacology & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBarrett's oesophagus (BE), the precursor to oesophageal adenocarcinoma, progresses through a stepwise dysplastic sequence. Accurate dysplasia detection is critical, as endoscopic eradication therapy is highly effective. The current standard of care is limited by poor real-world adherence to the Seattle protocol, sampling error, and significant interobserver variability in pathologic interpretation. Post-endoscopy oesophageal neoplasia rates approaching 26% underscore the need for improved detection of dysplasia.
aimsThis review evaluates emerging and established technologies for dysplasia detection, procedural efficiency, and risk stratification in Barrett's oesophagus surveillance.
methodsA narrative review of the published literature was performed, encompassing endoscopic imaging modalities, non-endoscopic sampling devices, artificial intelligence applications, and tissue and molecular biomarkers.
resultsVirtual chromoendoscopy increases dysplasia detection over white-light endoscopy and is recommended in current guidelines. Non-endoscopic capsule and balloon-based devices coupled with biomarker testing are currently used for BE screening, though evidence demonstrates strong performance for risk stratification of patients with known BE, which may expand their use into surveillance. Data suggest that wide-area transepithelial sampling with computer-assisted analysis increases adjunctive dysplasia detection. Artificial intelligence systems show high sensitivity and specificity for endoscopic and histopathologic dysplasia detection. Multiple biomarkers have been developed for risk stratification of patients with known BE and appear to aid in estimating individualized progression risk.
conclusionsA broad array of technologies shows promise in increasing dysplasia yield in patients with BE under surveillance. Most candidate solutions have not yet achieved sufficient validation to replace current practice. A multimodal, biomarker-driven, risk-stratified approach may substantially reduce missed neoplasia and improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.